Geneva, Sept. 25 -- International Clinical Trials Registry received information related to the study (NCT07817251) titled 'Research Study on How People With Type 2 Diabetes Tolerate Switching From Semaglutide to Cagrisema' on Sept. 8.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor).
Primary Sponsor: Novo Nordisk A/S
Condition:
Diabetes Mellitus, Type 2
Intervention:
Drug: CagriSema
Recruitment Status: Not recruiting
Phase: Phase 3
Date of First Enrollment: September 16, 2026
Target Sample Size: 210
Countries of Recruitment:
United States
To know more, visit...